Review of immunotherapy innovations for triple-negative breast cancer survival

Photo by Buddha Elemental 3D / Unsplash

Frontiers in Medicine Published April 23, 2026 Medically reviewed April 24, 2026 Study authors: Zi-Xin Wang, Ju-Hang Chu, Ya-Ru Wang, Lu-Yao Huang, Ming-Ping Qian DOI ↗ By Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development

Key Takeaway

Consider immunotherapy innovations for TNBC; survival may improve in PD-L1-positive metastatic disease.

This narrative review evaluates the role of immunotherapy innovations, such as immune checkpoint inhibitors (ICIs), combination strategies, and biomarker-driven therapy, in the management of triple-negative breast cancer (TNBC). The scope encompasses various medication classes including PD-1 inhibitors, PD-L1 inhibitors, chemotherapy, PARP inhibitors, and antibody-drug conjugates. The primary focus is on survival outcomes within this specific patient population.

The authors report that survival appears improved in PD-L1-positive metastatic TNBC when utilizing these immunotherapies relative to chemotherapy. However, the review does not provide specific effect sizes, absolute numbers, p-values, or confidence intervals for these findings. Furthermore, detailed safety profiles, including adverse events and tolerability, were not reported in the source material.

Significant limitations identified by the authors include tumor heterogeneity and the development of resistance mechanisms. Additionally, the review notes challenges related to access to advanced therapies. While the practice relevance is described as having the potential to redefine TNBC management, the lack of quantitative data and reported safety information necessitates cautious interpretation of these synthesized conclusions.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedApr 2026

View Original Abstract ↓

Triple-negative breast cancer (TNBC), an aggressive subtype lacking estrogen receptor (ER), progesterone receptor (PR), and HER2 expression, accounts for 10–20% of breast cancers and is characterized by high metastatic potential and poor survival outcomes. Despite advancements in chemotherapy, the 5-year survival rate for metastatic TNBC remains below 30%, underscoring the need for innovative therapeutic approaches. This review comprehensively examines recent breakthroughs in TNBC immunotherapy, focusing on immune checkpoint inhibitors (ICIs), combination strategies, and biomarker-driven therapy. Landmark trials such as KEYNOTE-355 and IMpassion130 have demonstrated that combining PD-1/PD-L1 inhibitors with chemotherapy improves survival in PD-L1-positive metastatic TNBC. Beyond monotherapy, combination therapies—including dual checkpoint inhibition, PARP inhibitors in BRCA-mutated tumors, and antibody-drug conjugates (ADCs) —show promise in overcoming resistance and enhancing antitumor immunity. Emerging targets further expand therapeutic possibilities, though their paradoxical roles as biomarkers and immunosuppressive mediators require precision-based approaches. Biomarkers like PD-L1, tumor-infiltrating lymphocytes (TILs), tumor mutational burden (TMB), and circulating tumor DNA (ctDNA) are critical for patient stratification and predicting immunotherapy response. Despite progress, challenges persist, including tumor heterogeneity, resistance mechanisms, and access to advanced therapies. Future directions emphasize next-generation ICIs, optimized combination regimens, and AI-driven biomarker integration to achieve durable, personalized treatments. This review underscores the potential of immunotherapy to redefine TNBC management while highlighting the imperative for continued innovation to address unmet clinical needs.